Centrus Energy Corp.
Centrus Reports Third Quarter 2026 Results
Revenue of $55.5 million, compared to revenue of $74.9 million in Q3 2025 GAAP net income of $31.6 million compared to GAAP net income of $3.9…
Archive
Press releases, November 2026
399 releases
Blue Owl Capital Corporation
Blue Owl Capital Corporation Announces September 30, 2026 Financial Results
Blue Owl Capital Corporation (NYSE: OBDC) ("OBDC" or the "Company") today announced financial results for its third quarter ended September 30, 2026.…
TriplePoint Venture Growth BDC Corp.
TriplePoint Venture Growth BDC Corp. Announces
Third Quarter 2026 Financial Results
Silvaco Group, Inc.
Silvaco Reports Third Quarter 2026 Financial Results
Won major new tier-1 FTCO customer and 4 tier-1 customers for Jivaro Pro in Q3
Granite Point Mortgage Trust Inc.
Granite Point Mortgage Trust Inc. Reports
Third Quarter 2026 Financial Results
Cytek Biosciences, Inc.
Cytek Biosciences Reports Third Quarter 2026 Financial Results
Klaviyo, Inc.
Klaviyo Delivers Solid Q3 with Enterprise Growth, Multi-Product Strength, and Agent Traction
Third quarter revenue of $387.2 million, representing 25% year-over-year growth
Flyte Aviation, Inc.
Flyte Aviation Executes Letter of Intent to Sell Cardiology Assets
Proposed Sale to include VIVO and LockeT Cardiac Electrophysiology product lines Divestiture would Complete the Company's Planned Transition to…
Piedmont Natural Gas
Piedmont Natural Gas lowers rates for North Carolina customers as winter heating season begins
Decrease is Piedmont's fifth rate reduction in North Carolina this year Billing programs and payment assistance to help customers manage bills Video:…
Adaptive Biotechnologies Corp
Adaptive Biotechnologies Reports Third Quarter 2026 Financial Results
Dianthus Therapeutics, Inc. /DE/
Advancing a neuromuscular franchise with claseprubart, a highly potent, investigational classical pathway inhibitor, with best-in-disease potential across generalized Myasthenia Gravis (gMG), Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), and Multifocal Motor Neuropathy (MMN)
Phase 3 EMERGE registrational trial of claseprubart in gMG evaluating 300mg/2mL Q2W and 300mg/2mL Q4W on track, with top-line results expected in…
FatPipe Networks
FatPipe, Inc. (FATN) Reports Q2 FY2027 Results: 22% Y-o-Y Q2 Revenue Growth and 24.1% Adjusted EBITDA Margin
FatPipe, Inc. (NASDAQ: FATN) ("FatPipe" or the "Company"), a pioneer and multiple patents holder in enterprise-class, application-aware, secure…
Outset Medical, Inc.
Outset Medical Reports Third Quarter 2026 Results
IM Cannabis Corp.
IM Cannabis Raises US$1,200,000 of Gross Proceeds in Convertible Note Financing
IM Cannabis Corp. ("IMCC" or the "Company") (Nasdaq: IMCC), a medical cannabis company with operations in Israel, today announced the closing of a…